Establishment of Mthera

Certified Corporate R&D Center(Korea Industrial Technology Association)

Angel Investment

Venture Business Certification(Korea Venture Capital Association)

Opening of Magok R&D Center

Selected as TIPS(Tech Incubator Program for Startup) Partners

SI Investment(1st&2nd)

US Patent granted for MT101 core material(No. 10,792,323)

Received ‘2020 Technical Innovation Enterprise Award’
(Hankookilbo, Sponsored by Ministry of SMEs and Startups & and Ministry of Trade, Industry and Energy)

Series A Investment

Received ‘2021 15th Korea Excellent Patent Award(Bioscience and Biotechnology)’
(Hankookilbo, Sponsored by Korea Institute of Patent Information)

Japan Patent granted for MT101 active ingredient(No. 6959446)

Opening of Series B1 Investment

Received ‘Korea Industry Award First-in-class Award’
(MONEYTODAY, Sponsored by Ministry of Trade, Industry and Energy & Ministry of Environment & Ministry of Education)

MT101(Pipeline for Parkinson's Disease), Selected as one of the “Top 100 Outstanding R&D Achievements for Solving Social Issues” by the Ministry of Science and ICT.

Initiation of P1 SAD study(NCT05844787) for MT101

Received ‘2022 16th Korea Excellent Patent Award(Bioscience and Biotechnology)’
(Hankookilbo, Sponsored by Korea Institute of Patent Information)

Series B1 Investment

MT101, Published in SCI journals(Biomed Pharmacother. 2022 Oct;154:113637.)

Received 6th Korea's Nobel Science Awards
‘Science Technology Creation Award’

MT104(Functional Food Ingredient for Cognitive Improvement),
Agri-food Products R&D Technical Commercialization Excellence Award(Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry)

Biotech Showcase(2023) Company Presentation

Japan Patent granted for MT101 core material(No. 7221207)

MT101, Awarded the Highest Grade(S) in the Final Evaluation of the ‘Bio-Medical Technology Development Program’ by the National Research Foundation of Korea(NRF)

MOU Execution with ‘The New England Medical Innovation Center(NEMIC) Foundation’

MT101, U.S. Phase 1 Clinical Trial complete

Participated in ‘2023 BIO USA’ and conducted 1:1 business meetups
(Selected as a participating company linked with the Korea Angel Investment Association's TIPS program)

Executed a Binding Term Sheet for the Licensing of MT9801
(Pipeline for Diabetic Neuropathy) with NeuroBo Pharmaceuticals

Selected for the “AI Data-Driven Bio-Leading Technology Development Project” by the Ministry of Science and ICT(MSIT)

MT101, Received IND Clearance for U.S. Phase 2a Clinical Trial(NCT06175767)

Opening of Series B2 Investment

US Patent granted for MT101 core material(No. 11,738,063)

Japan Patent granted for MT101 formulation composition(No. 7361903)

Awarded First Prize(Grand Prize) at the '2023 High Scale-up Demo Day’
(Hosted by the Korea Venture Capital Association(KVCA) & Kingo Invest)

Signed a MOU for the ‘Establishment of the Gangneung Natural Product Bio National Industrial Complex’(Ministry of Land, Infrastructure and Transport, Gangneung City, Korea Land & Housing Corporation [LH])

MT101(Pipeline for Inflammatory Bowel Disease), Selected for the “Scale-up TIPS” Program by the Ministry of SMEs and Startups

MT104, Selected as “Top 20 Outstanding Agricultural Food R&D Achievements in 2023”
(Ministry of Agriculture, Food and Rural Affairs)

Presented a Session on “Platform Technology” at the ‘2024 Spring International Convention of PSK’

MT101, Presented at the ‘The 2nd Natural Product Bio-Symposium’
(Hosted by the Korean Society of Pharmacognosy and KIST Natural Products Research Institute)

Executed an Exclusive License Agreement for MT9801 with MetaVia
(Formerly NeuroBo Pharmaceuticals)

Advancing the SyMthomics Platform Technology Commercialization

Presented a Session on “Platform Technology” at the ‘2024 Autumn Scientific Conference of the Korean Society of Medicinal Crop Science’

Participated in ‘2024 Bio Europe Fall’ and conducted 1:1 business meetups

Participated in the ‘2024 TIPS@Boston Global Open Innovation’ and Delivered an IR Presentation
(Selected as a participating company by the Korea Scale-up TIPS Association)

Participated in the ‘2024 Korea-Japan Startup Open Innovation Week’ and Delivered an IR Presentation
(Selected as a participating company by KITA and KVIC)

MOU Execution with ‘PL B&B’

US Patent granted for MT101 active ingredient(No. 12,226,395)

MT102, Received Approval and Initiated Phase 1 Clinical Trial in Korea (Chungbuk National University Hospital)

EU Patent granted for MT101 active ingredient(No. EP3701946)

Participated in ‘Bio Korea 2025’ and conducted 1:1 business meetups

MT104, Human Clinical Trial Results Published in SCI journals (J Med Food. 2025 Aug;28(8):812-823.)

EU Patent granted for MT101 formulation composition(No. EP4043024)

Participated in ‘BIOPLUS-INTERPHEX KOREA 2025’ and conducted 1:1 business meetups
(Selected as a participating company supported by Seoul BioHub)

MT101, Presented a Session at the '2025 Fall International Convention of The Pharmaceutical Society of Korea'

MT101, Published in SCI journals(Biomed Pharmacother. 2026 Mar;196:119094.)

EU Patent granted for MT101 core material(No. EP3539550)